The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Call it a major breakthrough for diagnostic imaging
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Subscribe To Our Newsletter & Stay Updated
